Refocus Group, Inc.
Refocus Group is a medical device company that develops surgical treatments for human vision disorders. Therapeutic targets include presbyopia (commonly known as farsightedness), elevated blood pressure in the eye, and a certain form of glaucoma. Its most advanced device is the Scleral Spacing Procedure, which includes an incision handpiece, implants, and related surgical equipment, that could treat the previously mentioned vision disorders. Medcare Investment owns more than half of the firm.
Contact Details
Executives
Chairman
Glen Bradley
President, CEO, and Director
Douglas C. (Doug) Williamson